Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.
Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug on January 25, 2024 at 5:48 am
